Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)

Brief Summary

In this study investigators are studying the effects of a drug called ketamine on the symptoms of Obsessive-compulsive disorder (OCD).

Intervention / Treatment

  • Drug: ketamine infusion
  • Other: Saline

Condition or Disease

  • Obsessive-Compulsive Disorder

Phase

Study Design

Study type: Interventional
Status: Completed
Study results: Has Results
Age: 18 Years to 55 Years   (Adult)
Enrollment: 15 ()
Funded by: Other

Masking

Clinical Trial Dates

Start date: Apr 10, 2020
Primary Completion: Dec 15, 2020
Completion Date: Dec 15, 2020
Study First Posted: Apr 08, 2010
Results First Posted: Oct 27, 2016
Last Updated: Feb 20, 2017

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

Obsessive-compulsive disorder (OCD) is a common psychiatric illness that affects up to 2-3% of the population. People with OCD experience anxiety-provoking, intrusive thoughts, known as obsessions, and feel compelled to perform repetitive behaviors, or compulsions. The only medications proven effective for OCD are serotonin reuptake inhibitors (SRIs), but even with SRI treatment, most patients continue to experience significant OCD symptoms, impaired functioning, and diminished quality of life. Recent evidence suggest that a different neurotransmitter, glutamate, may contribute to the symptoms in OCD. Medications that target glutamate hold promise for ameliorating symptoms for those patients continuing to suffer from OCD. In this study the investigators are recruiting patients to receive the drug ketamine, which is thought to modulate the neurotransmitter glutamate through the N-methyl-D-aspartate (NMDA), in a 2-week placebo controlled study.

Eligibility Criteria

Sex: All
Minimum Age: 18
Maximum Age: 55

More Details

NCT Number: NCT01100255
Other IDs: 6906R/5883
Study URL: https://ClinicalTrials.gov/show/NCT01100255
Last updated: Jun 17, 2022